SC Linn

430 citations

30 papers · 283 · h-index 8

Impact in

Cancer Research top 10%
- Breast Cancer Treatment Studies
Pathology and Forensic Medicine
- Breast Lesions and Carcinomas

Papers in

Cancer Research 16
- Breast Cancer Treatment Studies 12
- Cancer Genomics and Diagnostics 5
Oncology 14
- PARP inhibition in cancer therapy 4
- Cancer Treatment and Pharmacology 3

Co-authors: Hilde Rosing (2 shared papers)Jos A. van der Hage (4 shared papers)Luc J. A. Strobbe (2 shared papers)A. Helen Westenberg (2 shared papers)Thijs van Dalen (3 shared papers)Marjolein L. Smidt (2 shared papers)Marc B. I. Lobbes (2 shared papers)Vivianne C. G. Tjan‐Heijnen (2 shared papers)
Journals: Cancer Research (16 papers)Annals of Oncology (3 papers)European Journal of Cancer (2 papers)Scientific Reports (1 paper)Radiotherapy and Oncology (1 paper)
Partner nations: Netherlands United States Belgium

In The Last Decade

SC Linn

30 papers receiving 279 citations

Peers

Countries citing papers authored by SC Linn

Since Specialization

Citations

This map shows the geographic impact of SC Linn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by SC Linn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites SC Linn more than expected).

Fields of papers citing papers by SC Linn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by SC Linn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by SC Linn. The network helps show where SC Linn may publish in the future.

Co-authors

The 25 scholars most cited alongside SC Linn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with SC Linn Line = papers co-authored together SC Linn links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08) BMC Cancer ·Lori M. van Roozendaal, M. Vane, Thijs van Dalen, Jos A. van der Hage, Luc J. A. Strobbe, Liesbeth Boersma, SC Linn, Marc B. I. Lobbes, Philip Poortmans, Vivianne C. G. Tjan‐Heijnen, K. K. B. T. Van de Vijver, Jolanda De Vries, A. Helen Westenberg, A. G. H. Kessels, Johannes H.W. de Wilt, Marjolein L. Smidt	2017	101
2	Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen Breast Cancer Research and Treatment ·Nynke G L Jager, Hilde Rosing, Jan H.M. Schellens, J. H. Beijnen, SC Linn	2014	28
3	A real or apparent decrease in glomerular filtration rate in patients using olaparib? European Journal of Clinical Pharmacology ·Maaike A. C. Bruin, Catharina M. Korse, B. van Wijnen, Vincent M. T. de Jong, SC Linn, B. van Triest, Hilde Rosing, Jos H. Beijnen, Daan van den Broek, Alwin D. R. Huitema	2020	26
4	Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial European Journal of Cancer ·Siu W. Lam, S.M. de Groot, A.H. Honkoop, Agnes Jager, Albert J. ten Tije, Monique M.E.M. Bos, SC Linn, Jackie Bosch, Judith R. Kroep, J.J. Braun, Harm van Tinteren, Epie Boven	2014	25
5	Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial Annals of Oncology ·Marleen Kok, Hugo M. Horlings, K. Van de Vijver, T. Wiersma, Nicola S. Russell, Leonie Voorwerk, Karolina Sikorska, Erik van Werkhoven, Ingrid A.M. Mandjes, Inge Kemper, J. Foekema, Sofie Wilgenhof, Myriam Chalabi, Jacqueline M. Stouthard, Gabe S. Sonke, Dana Cullen, Roberto Salgado, Ton N. Schumacher, Christian U. Blank, SC Linn	2017	21
6	Abstract S1-03: First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer Cancer Research ·VC Tjan-Heijnen, IE van Hellemond, P.G.M. Peer, AC Swinkels, CH Smorenburg, Maurice van der Sangen, Judith R. Kroep, H. de Graaf, AH Honkoop, F. Erdkamp, FW van den Berkmortel, JJ Kitzen, Maaike de Boer, W. de Roos, SC Linn, A. Imholz, Caroline Seynaeve	2017	20
7	Abstract OT2-1-02: Clinical node negative breast cancer patients undergoing breast conserving therapy: follow-up versus sentinel lymph node biopsy Cancer Research ·LM van Roozendaal, M. Smidt, HHW de Wilt, T van Dalen, L.J.A. Strobbe, Jos A. van der Hage, VCG Tjan-Heijnen, SC Linn, JL Serroyen	2012	8
8	Predicting response to alkylating chemotherapy in breast cancer patients using array comparative genomic hybridization. Cancer Research ·MA Vollebergh, P.M. Nederlof, LF Wessels, Marjanka K. Schmidt, SA Joosse, Erik van Beers, Femke E. Froklage, M. Holtkamp, JG Schrama, Jelle Wesseling, Michael Hauptmann, ML de Bruin, Sjoerd Rodenhuis, SC Linn	2009	8
9	Quality assurance of radiation therapy after breast-conserving surgery among patients in the BOOG 2013-08 trial Radiotherapy and Oncology ·V. Wintraecken, Liesbeth Boersma, Lori M. van Roozendaal, J. de Vries, Sander M. J. van Kuijk, M. Vane, Thijs van Dalen, Jos A. van der Hage, Luc J. A. Strobbe, SC Linn, Marc B. I. Lobbes, Philip Poortmans, Vivianne C. G. Tjan‐Heijnen, K.K.B.T. van de Vijver, A. Helen Westenberg, Johannes H. W. de Wilt, Marjolein L. Smidt, Janine M. Simons	2023	7
10	PD07-07: Combination of Paclitaxel and Bevacizumab without or with Capecitabine as First-Line Treatment of HER2−Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): First Results from a Randomized, Multicenter, Open-Label, Phase II Study of the Dutch Breast Cancer Trialists' Group (BOOG). Cancer Research ·SW Lam, SM de Groot, AH Honkoop, Agnes Jager, AJ ten Tije, M.M.E.M. Bos, SC Linn, Bosch J van den, JWR Nortier, JJ Braun, H. de Graaf, JEA Portielje, Maartje Los, D. J. de Gooyer, Harm van Tinteren, Epie Boven	2011	4
11	Abstract S3-05: Higher 10-year overall survival after breast conserving therapy compared to mastectomy in early stage breast cancer: A population-based study with 37,207 patients Cancer Research ·MC van Maaren, Linda de Munck, Geertruida H. de Bock, JJ Jobsen, Thijs van Dalen, Philip Poortmans, SC Linn, L.J.A. Strobbe, Sabine Siesling	2016	4
12	Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with early breast cancer: results from the TEAM trial neuropsychological side study. Cancer Research ·CM Schilder, C Seynaeve, SC Linn, Willem Boogerd, Beex Lv, CM Gundy, HM Huizenga, J.W.R. Nortier, CJ v d Velde, FS van Dam, S B Schagen	2009	4
13	A new independent validation of the 70-gene signature in node-negative breast cancer European Journal of Cancer Supplements ·J.M. Bueno de Mesquita, Rosalinde M. Keijzer, SC Linn, A.A.M. Hart, C. van Krimpen, Carel Meijers, Laura van ‘t Veer, Marc J. van de Vijver	2006	3
14	Selective benefit of high-dose, platinum-containing, alkylating chemotherapy with stem cell rescue for patients with breast cancers with an expansive growth pattern on histology Journal of Clinical Oncology ·SC Linn, Marieke A. Vollebergh, Michael Hauptmann, LF Wessels, Petra M. Nederlof, Elisabeth G.E. de Vries, Sjoerd Rodenhuis, Jelle Wesseling	2009	3
15	Cox proportional hazards regression in small studies of predictive biomarkers Scientific Reports ·Katarzyna Jóźwiak, Vy H. Nguyen, Lukas Sollfrank, SC Linn, Michael Hauptmann	2024	2
16	Complete remission of colorectal cancer: a pitfall in a multidrug resistance reversal trial The Lancet ·SC Linn, Giuseppe Giaccone, C.K. van Kalken, Paul van der Valk, C.M. Kuiper, Herbert M. Pinedo	1994	2
17	Abstract OT2-07-08: Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trial Cancer Research ·S.B. Vliek, Agnes Jager, M. Jonge-Lavrencic, JP Lotz, Anthony Gonçalvès, Monika Graeser, Ulrike Nitz, IAM Mandjes, MJ Holtkamp, Margaret Schot, Valesca P. Retèl, EJ Kuip, MN Wymenga, IR Konings, VCG Tjan-Heijnen, Judith R. Kroep, C. Schroeder, Elsken van der Wall, SC Linn	2018	2
18	Abstract S6-02: The efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone-receptor positive early breast cancer. First results of the TEAM IIB trial (BOOG 2006-04) Cancer Research ·SB Vliek, Elma Meershoek‐Klein Kranenbarg, AGJ van Rossum, BC Tanis, Hein Putter, AWG van der Velden, MP Hendriks, A van Bochove, Yvonne van Riet, AE van Leeuwen-Stok, VCG Tjan-Heijnen, Judith R. Kroep, JWR Nortier, CJH van de Velde, SC Linn	2017	2
19	Abstract PD5-02: The effect of trastuzumab-based therapy on overall survival in small, node-negative HER2-positive breast cancer: To treat or not to treat? Cancer Research ·MS van Ramshorst, M van der Heijden-van der Loo, GMHE Dackus, SC Linn, GS Sonke	2016	2
20	Selecting patients with oligo-metastatic breast cancer harboring homologous recombination deficiency (HRD) for intensified chemotherapy: The OLIGO-study Annals of Oncology ·Tessa G. Steenbruggen, Astrid N. Scholten, M-J.T. Vrancken-Peeters, Ingrid A.M. Mandjes, M. Holtkamp, Jelle Wesseling, SC Linn, Gabe S. Sonke	2017	1

About SC Linn

SC Linn is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Genetics, having authored 30 papers that have together received 283 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (12 papers), Advanced Breast Cancer Therapies (7 papers), BRCA gene mutations in cancer (5 papers), Cancer Genomics and Diagnostics (5 papers), Breast Lesions and Carcinomas (5 papers), PARP inhibition in cancer therapy (4 papers), DNA Repair Mechanisms (4 papers) and Cancer Treatment and Pharmacology (3 papers). The work is most often cited by research in Cancer Research (168 citations), Pathology and Forensic Medicine (96 citations), Oncology (138 citations), Immunology (36 citations) and Surgery (68 citations). SC Linn has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Hilde Rosing, Jos A. van der Hage, Luc J. A. Strobbe, A. Helen Westenberg, Thijs van Dalen, Marjolein L. Smidt, Marc B. I. Lobbes, Vivianne C. G. Tjan‐Heijnen, Liesbeth Boersma and Lori M. van Roozendaal. Their work appears in journals such as Cancer Research, Annals of Oncology, European Journal of Cancer, Scientific Reports and Radiotherapy and Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

SC Linn

Impact in

Papers in i

In The Last Decade

SC Linn

Peers

Countries citing papers authored by SC Linn

Fields of papers citing papers by SC Linn

All Works

About SC Linn

Explore authors with similar magnitude of impact

Papers in